DNV, an EU Notified Body for the In Vitro Diagnostic Medical Devices Regulation (IVDR), announced on Wednesday that it has issued an IVDR certificate to China-based FAMID Biomedical Technology (Tianjin) Co Ltd for its diagnostic test designed to support the early detection of cervical cancer.
According to DNV, the certification was completed in just six months, following assessment of the manufacturer's quality management system, clinical evidence and technical documentation.
FAMID Biomedical's newly certified E7 Oncoprotein Rapid Test Kit, classified as a Class C in vitro diagnostic medical device under the IVDR, is designed as an aid in the diagnosis of cervical epithelial cell lesions through the detection of HPV E7 oncoprotein in cervical cell samples. The product is intended for both professional laboratory use and self-testing.
Inhibrx updates clinical data for ozekibart (INBRX-109) in Ewing sarcoma
Onward Therapeutics closes Series B financing
Oncoinvent reports favourable interim safety results for Radspherin in phase 2 ovarian cancer trial
Apotex launches generic version of INLYTA in US market
Akeso submits sNDA for ivonescimab chemotherapy combination in first-line biliary tract cancer
Specialised Therapeutics' YONDELIS sarcoma therapy approved in Thailand
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism